Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
WILMINGTON, Del., March 17, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of Imprivata, Inc. (NYSE:IMPR)?
- Did you purchase your shares between July 30, 2015 and November 2, 2015, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of Imprivata, Inc. (“Imprivata” or the “Company”) (NYSE:IMPR) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities that purchased the common stock of Imprivata between July 30, 2015 and November 2, 2015, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you wish to serve as lead plaintiff, you must move the Court no later than April 4, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of Imprivata during the Class Period, or purchased shares prior to the Class Period and still hold Imprivata, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/imprivata-inc-impr.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
